MET and central nervous system cancer: miR-34a is a p53 transcriptional target poorly expressed in HGG compared to normal brain tissues [93], and it is known to suppress in vitro and in vivo tumor growth by targeting c-MET and NOTCH, thus directly modulating glioma cell cycle [94].